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Abstract
Background: Positron emission tomography computerized tomography (PET-CT) is useful in radiotherapy planning for lung cancer. 
However, its role in malignant pleural mesothelioma (MPM) is unknown.
Objectives: This exploratory study investigated the possible role for PET-CT in radiotherapy planning for MPM.
Patients and Methods: Patients receiving radiotherapy for the treatment of pain in MPM, had fluorodeoxyglucose (FDG) PET-CT scanning 
in addition to their standard CT scan. PET-CT images were then fused with CT planning images, termed Planning-PET-CT. Target volume 
delineation was undertaken first using CT and subsequently incorporated Planning-PET-CT. Planning treatment volume (PTV), conformity 
index (CI), mean distance to conformity (MDC), center of gravity distance (CGD) and standard uptake values (SUV) were examined.
Results: Sixteen patients were recruited into the study. PET-CT upstaged nine patients. No association between SUV max and either survival 
or pain response was seen. Volumes contoured using Planning-PET-CT differed markedly from those outlined using CT alone as shown by the 
following parameters: CI = 0.3 (0.24 - 0.38). MDC = 21.47 (16.73 - 33.70) and CGD = 16.40 (11.80 - 33.87). The median percentage of over contouring 
was 44.00% (34.33 - 72.50) with 46.67% under contoured (34.00 - 55.00).
Conclusions: PET-CT alters the position of the PTV in MPM and upstaged a proportion of patients. Further work to elucidate the role of 
Planning-PET-CT in target volume definition is justified.
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1. Background
Malignant pleural mesothelioma (MPM) is associated 
with a median life expectancy of approximately one year 
(1). Therefore, the majority of patients with MPM are treat-
ed with palliative intent, with the emphasis on symptom 
control. The most common symptom in MPM is pain, 
which is often very difficult to treat (1, 2). While opioids, 
adjuvant analgesics and even interventional anaesthesia 
are often employed, radiotherapy remains a commonly 
used treatment. However, there is a paucity of data to 
support its use in this setting. Based on current available 
evidence, it is difficult to offer an accurate estimate of the 
likely benefit from radiotherapy for treating pain in MPM 
with response rates quoted between 0 and 69% (3).
One of the possible reasons for this huge variability in 
response to radiotherapy for treating pain in MPM is that 
radiotherapy planning in MPM is challenging. MPM affects 
the lining of the entire lung and, as a result, pain is often 
diffuse. The treating oncologist must balance the risks and 
possible toxicities of treating large volumes with the risk of 
failing to achieve pain control if smaller volumes are treat-
ed. At present, techniques for planning and treating MPM 
with palliative radiotherapy are crude. The area of pain in 
MPM is often widespread and may or may not correspond 
to disease bulk on CT imaging. The treating radiotherapist 
may have to compromise by directing treatments to areas 
of disease which may or may not wholly correspond to 
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pain. There is a need to optimize radiotherapy planning in 
MPM with the ultimate aim of improving response.
One possible method for achieving this is through us-
ing positron emission tomography-computed tomogra-
phy (PET-CT) scanning in radiotherapy planning. The role 
of PET-CT in radiotherapy planning is established in some 
cancers and, in non-small cell lung cancer (NSCLC), is rec-
ommended for routine use in this setting (4).
Preliminary work examining the value of PET-CT in 
radical radiotherapy planning and assessing response to 
chemotherapy in MPM has been performed (5, 6). To our 
knowledge, its role in palliative radiotherapy planning 
in MPM has not been explored, particularly in terms of 
defining optimum treatment volumes. We hypothesised 
that incorporating PET-CT into radiotherapy planning for 
treating pain in MPM might improve target volume defi-
nition, resulting in better pain control.
2. Objectives
Therefore, the aim of the present study was to explore 
the role of PET-CT in radiotherapy planning for the treat-
ment of pain in MPM.
3. Patients and Methods
As part of a multi-centre prospective single-arm phase 
II study examining the role of radiotherapy for the treat-
ment of pain in MPM (ISRCTN 10644347), a subgroup of 
patients underwent PET-CT scanning. The study was per-
formed in a regional cancer center in the UK. The study 
was approved by the institutional review board and all 
subjects provided written informed consent.
Eligible patients were 18 years of age or over, had a di-
agnosis of MPM (histological or multidisciplinary team), 
mesothelioma related pain for which radiotherapy was 
planned, a life expectancy of at least three months and 
a performance status of 0 - 2 (Eastern Cooperative Oncol-
ogy Group-ECOG). Consecutive patients were recruited 
from May 2012 until December 2013.
All patients underwent CT-based radiotherapy planning 
prior to PET-CT imaging. All planning CTs were captured on 
a light speed simulator LS RT 16 GE Medical CT scanner (GE 
Medical systems, Crawley, UK) using a 120 kV automatic mA 
modulation range of 15 - 240 mAs with 50 cm dual field of 
view. Radio-opaque wire markers were positioned on the 
patient on the outer aspects of the painful areas to help cor-
relate clinical and radiological findings. Gross tumour vol-
ume (GTV) was defined as the volume of tumour that was 
felt by the clinician to be responsible for the pain. The GTV 
to PTV margin was 1.5 cm. All patients were treated with 20 
Gy in five fractions using a Varian Linear Accelerator.
Prior to undergoing PET-CT imaging, patients were fast-
ed for at least six hours and then imaged one hour after 
injection of 400 MBq Fluorine-18-Fluorodeoxyglucose 
(18F-FDG). Imaging was performed using an integrated 
PET-CT system (Discovery-690, general electric (GE) sys-
tem, Milwaukee, WI, USA). To replicate the radiotherapy 
treatment position, patients were positioned supine on a 
radiotherapy flat bed insert and immobilized using a CIV-
CO posirest-2. LAP lasers were then used to position the 
patient centrally in the scanner. Whole body CT images 
were acquired using a 120 kV automatic mA modulation 
range of 15 - 240 mAs. The encompassed field of view was 
from the skull base to the upper thigh, with reconstruc-
tions performed at 2.5 mm increments. This was followed 
by whole body PET acquisition, encompassing the same 
transverse field of view as the CT. PET attenuation correc-
tion was based on the CT data and images were corrected 
for scatter and iteratively reconstructed using time of 
flight and SharpIR on a 192 × 192 matrix. All acquired im-
ages and SUV data were exported to a dedicated GE work-
station (ADW 4.5) for viewing and reporting.
PET-CT images were assessed together three months 
after the final patient received radiotherapy in order to 
reduce recall bias. PET-CT images were transferred to a ra-
diotherapy treatment planning system (Eclipse 10.0.42) 
and into a DICOM RT format. PET-CT images were then 
fused with CT planning images, termed Planning-PET-
CT. The window and level for the PET images were set ac-
cording to a previously described protocol using a 7 g/mL 
threshold (7). To enable evaluation of whether SUV cor-
related with pain, maximum SUV (g/mL based on body 
weight) were recorded for both irradiated tumour and 
for tumour out with the radiation field.
Contouring was performed independently by three 
clinicians. Each clinician outlined a GTV and PTV based 
initially on the standard radiotherapy planning CT scan. 
Once each clinician had contoured all patients, they were 
then permitted access to the E-PET-CT. At this time, each 
clinician re-contoured a GTV and PTV using the E-PET-CT 
images again for all patients.3.1. Statistical Procedures
The difference in overall treatment volumes (%) between 
CT and Planning-PET-CT was assessed. The concordance in 
volumes (GTV) outlined between CT and Planning-PET-CT 
was calculated using the conformity index (CI). A CI of 1 
represented complete concordance between the CT and 
Planning-PET-CT, while a value of 0 represented no con-
cordance (8).
CT was defined as the reference parameter and Plan-
ning-PET-CT was the evaluation parameter. The difference 
in shape of treatment areas between CT and Planning-
PET-CT was assessed using mean distance to conformity 
(MDC). The center of gravity distance (CGD) assessed the 
difference from the central point of the reference vol-
ume and the evaluation volume. The under contoured 
volume (UCV) was the volume that was contoured in the 
reference volume, but not contoured in the evaluation 
volume and is expressed in %. The over contoured volume 
(OCV) is the volume that is contoured in the evaluation 
volume that is not contoured in the reference volume 
and is expressed in %. These parameters were calculated 
using ImsimQA version 3.0.77.
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Patients whose pain improved following radiotherapy 
were defined as pain responders. A pain response was de-
fined as a 30% drop in the brief pain inventory (BPI) score 
5 weeks after radiotherapy.
To facilitate analysis, parameters were averaged across 
the clinicians for each patient. The comparison between 
Planning-PET-CT and CT was made using a Wilcoxon 
signed rank test. All analyses were performed in SPSS 
v22.0 (Chicago IL.). An exploratory analysis of maximum 
standard update value (SUV) was performed to see if 
there was any potential association between these values 
and pain response or overall survival.
4. Results
Sixteen patients were recruited and patient characteris-
tics are shown in Table 1. All patients had a histological di-
agnosis of MPM. The majority of patients were male (n = 14) 
and the median age (IQR) was 75 years old (65 - 79). Median 
survival was 4.1 months (95% CI: 2.6 months to 5.5 months) 
from time of study registration. One patient was excluded 
from the study as he had a small, palpable tumour lump 
that was delineated by palpation rather than using imag-
ing. Therefore, 15 patients were included in the analysis. In 
all patients, there was abnormal SUV uptake in the thorax.
PET-CT resulted in upstaging of 9 of the 16 patients 
(56%), compared with conventional CT imaging. One pa-
tient was upstaged from T3 to T4 (6%), four patients had 
upstaging of nodal disease (25%) and five patients were 
found to have metastatic disease (31%), one of whom also 
had nodal upstaging. In two of these patients, this led 
to palliative radiotherapy being delivered, one of whom 
had impending spinal cord compression at the level of C5 
which was above the scanning level of the staging CT, as 
seen in Figure 1. The bone metastases were not seen on 
the conventional CT of either patient.
Differences in PTV volumes delineated using CT and 
Planning-PET-CT are shown in Figure 2. In nine patients, 
PTV was larger when delineated using Planning-PET-CT 
compared with CT and in six patients it was smaller. Me-
dian Planning-PET-CT defined volume was increased by 
4.14% compared with CT (IQR: -32.09% smaller to +22.25%) 
but this was not statistically significant (P = 0.65).
Table 1. Patient Demographics a
No. (%)
Gender (M/F) 14/2 (87.5/12.5)
PS (ECOG) 0/1/2 2/9/4 (13/60/27)
Mesothelioma Histology
Sarcomatoid 3 (18.8)
Epithelioid 11 (68.8)
Mixed 2 (12.5)
Previous Mesothelioma Therapy
Chemotherapy 5 (33)
Radiotherapy 0 (0)
a  (n = 16).
Analysis of CI, MDC, CGD, under/over-contouring and 
volume mismatch is shown in Table 2. The low value for 
CI (0.30) and high values for MDC (21.47 mm) and CGD 
(16.40 mm) as well as the high percentage of over- and 
under-contouring (44.00 and 46.67%, respectively), in-
dicate significant discrepancies in the anatomical loca-
tion of volumes outlined using CT or Planning-PET-CT. 
Figures 3 and 4 show representative images illustrating 
differences in GTV contouring between individual clini-
cians when CT and Planning-PET-CT datasets were used to 
guide volume delineation.
At the time of PET-CT acquisition, median blood glucose 
concentration was 5.0 mmol/L (range 4.2 - 6.3). Median 
SUV max was 17.6 (IQR 12.5 - 23.0). Median survival in pa-
tients with SUV max less than 17.6 was 3.7 months (95% 
CO 3.3 - 4.1) compared with 4.1 months (95% CI 0 - 9.6) for 
patients with SUV max greater than 17.6, a difference that 
was not statistically significant.
Figure 1. PET-CT Image Showing Impending Spinal Cord Compression, 
Not Seen With Conventional CT
Figure 2. Waterfall Plot of Median Percentage Difference in Volumes (%) 
Outlined by E-PET-CT and CT
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A positive difference indicates the volume outlined with E-PET-CT is greater 
than with CT alone (n = 15).
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Table 2. Summary Data of Key Parameters Comparing CT Alone 
Compared With E-PET-CT a,b
Parameter, Unit/Range Median IQR
CI (0 - 1) 0.30 0.24 - 0.38
MDC, mm 21.47 16.73 - 33.70
Volume difference, % 4.14 -32.09 - 22.25
Total volume mismatch, % 92.33 77.33 - 130.33
CGD, mm 16.40 11.80 - 33.87
UC Vol, % 44.00 34.33 - 72.50
OC Vol, % 46.67 34.00 - 55.00
a  n = 15.
b  Abbreviations: CI, conformity index; CGD, centre of gravity distance;
MDC, mean distance to conformity; OC Vol, over contoured volume;
UC Vol, under contoured volume.
Figure 3. CT Image Showing the Differences in GTV Outlining Using CT Alone 
by 3 Clinicians -Green-Clinician 1, Pink-Clinician 2 and Cyan-Clinician 3
The liver is contoured yellow.
Figure 4. An E-PET-CT Image Showing the Differences in Voluming Using 
E-PET-CT by 3 Clinicians-Green-Clinician 1, Pink-Clinician 2 and Cyan-
Clinician 3
The liver is contoured yellow.
There was an association between SUV max and pain 
with SUV max being higher in the irradiated area than 
the non-irradiated area. The median difference in SUV 
max between these areas was 4.0 (IQR 0.8-8.6), P = 0.035.
Mean SUV max for pain responders was 17.4 compared 
with 18.1 for non-responders. The variability and differ-
ence in group sizes makes it impossible to draw any ro-
bust conclusions about differences between responders 
and non-responders using SUV parameters.
5. Discussion
These findings show that incorporation of PET-CT imag-
ing in the radiotherapy planning process alters the ana-
tomical location of the target volume in patients with 
MPM. There was an association between SUV max and 
location of pain with the painful (irradiated) area having 
a higher SUV max than the non-painful (non irradiated) 
area. This did not translate into increased response rates 
to radiotherapy in patients with higher SUV max values. 
PET-CT also upstaged a large percentage of patients. In 
two patients this led to palliative radiotherapy being 
delivered to sites of painful bony disease. One of these 
patients had imminent spinal cord compression in the 
cervical spine.
Comparing our findings to previous work is difficult 
as, to date, only one other study has examined PET-CT 
in radiotherapy planning in MPM (6). Pehlivan and co-
workers examined 13 patients and outlined GTV and PTV 
using both CT and fused PET-CT. All target volume delin-
eation was performed by one radiation oncologist and 
checked by another. The GTV comprised of macroscopic 
primary tumour along with involved hilar and medias-
tinal lymph nodes. The authors found that in 12 of the 
13 patients, the GTV and PTV were significantly smaller 
when using the fused PET-CT images, with a mean GTV 
reduction of 47.1% (+/- 28.4%). The main difference be-
tween this previous work and the present study is that 
we assessed palliative radiotherapy planning as op-
posed to radical radiotherapy. This may well account for 
differences in the findings.
The present study therefore increases the knowledge 
base in two ways. Firstly, the use of PET-CT significantly al-
ters the location of the target volume. It is also of interest 
that SUVmax was higher in the irradiated areas, which by 
default, were the areas where pain was the most severe. 
This association has not previously been reported in lung 
cancer or MPM per se, however, it has been demonstrated 
that increased SUV uptake is associated with increased 
pain and subsequent response to radiotherapy in bone 
metastases (9). The present study was not powered to 
examine whether increased SUVmax predicted increased 
likelihood of response to radiotherapy, but this would be 
of interest in future work. Indeed PET-CT based treatment 
planning could be used to target all metabolically active 
disease, which presumably, causes the most pain.
Secondly, PET-CT upstaged a large proportion of patients 
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and therefore, it should be considered as a staging inves-
tigation when radical treatment is being considered.
This places PET-CT in a favorable light and the utility 
of this is supported by its increasing use in MPM. It can 
play a role in differentiating benign from malignant 
lesions and help target the most suitable lesion for bi-
opsy (10). In addition, it has been shown to be effective 
in pre-operative imaging, particularly with regards to 
detecting distant metastases (11, 12). Given the diffuse, 
infiltrative nature and asymmetric growth pattern of 
MPM, measuring response to treatment with CT is ex-
tremely difficult. One study looked at changes in total 
glycolytic volume (TGV) in PET-CT and suggested that 
a decrease in TGV after chemotherapy, related to a sur-
vival advantage (13).
PET-CT can also be helpful for radiotherapy planning 
when there is significant atelectasis. Although contour-
ing with PET-CT is generally smaller that with CT alone, 
one study did show that contouring with PET-CT can 
produce larger volumes than when contouring with CT 
which may be due to resolution effects (14).
PET-CT may also be useful in estimating prognosis. For 
instance, the presence of metastatic disease on PET-CT 
has, not surprisingly, been shown to be associated with 
poorer survival (15). Furthermore, one study showed that 
patients who had an SUVmax greater than 10 had de-
creased survival (16). These findings were not replicated 
in the present study though this may be due to the small 
sample size and number of survival events. It is impor-
tant to emphasize that there are many factors which can 
influence the SUV value such as blood glucose and timing 
from injection of the FDG to acquisition of the images, so 
making cross study comparisons is difficult (17).
The current study has limitations. Although it is the larg-
est study to date looking at PET-CT in radiotherapy plan-
ning in MPM, the sample size is small which is a peren-
nial problem in rare cancers. Furthermore, on reviewing 
the size of the GTV outlined by each clinician, it became 
clear that there was widespread variation in contouring. 
This degree of subjectivity is difficult to avoid since it is 
not known whether covering all PET avid disease is neces-
sary for radiotherapy to be effective in terms of reducing 
pain. It is not known whether treating central disease is 
necessary or whether radiotherapy should focus on more 
peripheral disease, looking for instance, for chest wall in-
vasion or nerve root irritation.
The present study demonstrates that PET-CT changes 
multiple parameters compared to CT alone, including 
the conformity index, center of gravity distance and 
contouring (both over and under). PET-CT also resulted 
in upstaging in a significant percentage of patients and 
should be considered as a staging investigation prior to 
any radical treatment.
Furthermore, the incorporation of PET-CT into the ra-
diotherapy planning process alters the location of the 
target volume in MPM. If PET parameters (such as SUV-
max) are useful in target delineation, this may result in 
improved palliation and pain control. Future studies ex-
amining this are awaited with interest.
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